Takeda Pharmaceutical Company Limited (TAK)

JP — Healthcare Sector
Peers: HLN  A  CAH  INSM  IQV  ALC  RMD  VEEV  EW  BDX 

Automate Your Wheel Strategy on TAK

With Tiblio's Option Bot, you can configure your own wheel strategy including TAK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol TAK
  • Rev/Share 1420.0126
  • Book/Share 2421.2866
  • PB 1.1285
  • Debt/Equity 0.635
  • CurrentRatio 1.194
  • ROIC 0.0154

 

  • MktCap 8630790854497.493
  • FreeCF/Share 302.7969
  • PFCF 9.0224
  • PE 75.2132
  • Debt/Assets 0.315
  • DivYield 0.0343
  • ROE 0.0161

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Resumed TAK Morgan Stanley -- Overweight -- -- Jan. 13, 2026
Upgrade TAK Morgan Stanley Equal Weight Overweight -- -- April 2, 2025

News

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
TAK
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral

TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent (Aged 12 Years and Above) and Adult Patients with HAE.1 The Pre-Filled Pen Option is Designed to Allow for An Individualized Treatment Approach for Adolescent and Adult HAE Patients. In the EU, TAKHZYRO is Approved for Routine Prevention of Recurrent HAE Attacks in Patients Aged 2 Years and Older.1 ZURICH , Feb. 24, 2025 /PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) announced today that the EMA has approved an additional 2 mL pre-filled pen option for TAKHZYRO® (lanadelumab) for subcutaneous administration in …

Read More
image for news The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
TAK vs. DSNKY: Which Stock Is the Better Value Option?
DSNKY, TAK
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Neutral

Investors with an interest in Medical - Drugs stocks have likely encountered both Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).

Read More
image for news TAK vs. DSNKY: Which Stock Is the Better Value Option?

About Takeda Pharmaceutical Company Limited (TAK)

  • IPO Date 2010-01-05
  • Website https://www.takeda.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Christophe Weber
  • Employees 49281
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.